Abstract
The platelet-derived growth factor (PDGF-A, PDGF-B, PDGF-C, PDGF-D) family is composed of homo- and hetero-dimers that are potent mitogens for a wide variety of cell types. They exert their biological effects by binding to two receptor tyrosine kinases (α- and β-PDGFR). PDGF-AA, -AB, -BB and -CC dimers bind to the α-PDGFR with high affinity, whereas PDGF-BB and -DD dimers bind to β-PDGFR. Aberrant PDGF signaling leads to increased interstitial fluid pressure, stromal cell recruitment and neo-angiogenesis in glioblastoma multiforme (GBM) due to deregulated autocrine/paracrine signaling. Therefore, targeting the PDGFR tyrosine kinase domain with small molecule tyrosine kinase inhibitors (TKIs) alone or in combination with chemotherapy may provide therapeutic benefit in GBM. Here we review PDGFR antagonists in clinical development including novel multi-targeted TKIs.
Keywords: Platelet derived growth factor receptor, Tyrosine Kinase Inhibitors, Glioblastoma Multiforme, Clinical trials
Letters in Drug Design & Discovery
Title: The Development of PDGF Receptor Inhibitors for the Treatment of Glioma: A Review
Volume: 7 Issue: 4
Author(s): Michael A. Badruddoja, Emad Elquza, James Welsh, Laurence Cooke, Abhay Sanan, Baldassrre Stea and Daruka Mahadavan
Affiliation:
Keywords: Platelet derived growth factor receptor, Tyrosine Kinase Inhibitors, Glioblastoma Multiforme, Clinical trials
Abstract: The platelet-derived growth factor (PDGF-A, PDGF-B, PDGF-C, PDGF-D) family is composed of homo- and hetero-dimers that are potent mitogens for a wide variety of cell types. They exert their biological effects by binding to two receptor tyrosine kinases (α- and β-PDGFR). PDGF-AA, -AB, -BB and -CC dimers bind to the α-PDGFR with high affinity, whereas PDGF-BB and -DD dimers bind to β-PDGFR. Aberrant PDGF signaling leads to increased interstitial fluid pressure, stromal cell recruitment and neo-angiogenesis in glioblastoma multiforme (GBM) due to deregulated autocrine/paracrine signaling. Therefore, targeting the PDGFR tyrosine kinase domain with small molecule tyrosine kinase inhibitors (TKIs) alone or in combination with chemotherapy may provide therapeutic benefit in GBM. Here we review PDGFR antagonists in clinical development including novel multi-targeted TKIs.
Export Options
About this article
Cite this article as:
Badruddoja A. Michael, Elquza Emad, Welsh James, Cooke Laurence, Sanan Abhay, Stea Baldassrre and Mahadavan Daruka, The Development of PDGF Receptor Inhibitors for the Treatment of Glioma: A Review, Letters in Drug Design & Discovery 2010; 7 (4) . https://dx.doi.org/10.2174/157018010790945887
DOI https://dx.doi.org/10.2174/157018010790945887 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Arsenic trioxide Alters the MicroRNA Expression Profile of U87 glioblastoma
Anti-Cancer Agents in Medicinal Chemistry Targeting p53 in Cancer
Current Medicinal Chemistry - Anti-Cancer Agents Targeting Angiogenesis in Head and Neck Cancer
Current Cancer Drug Targets Molecular Basis for the Neuroprotective Properties of FKBP-Binding Immunophilin Ligands
Current Medicinal Chemistry - Central Nervous System Agents Nanocarriers for Effective Brain Drug Delivery
Current Topics in Medicinal Chemistry Discovery of Small Molecules that Target Autophagy for Cancer Treatment
Current Medicinal Chemistry Fusogenic Oncolytic Herpes Simplex Viruses as a Potent and Personalized Cancer Vaccine
Current Pharmaceutical Biotechnology NMR in Metabolic Profiles of Neural Stem/Progenitor Cells: Current Status and Relevant Problems
Current Medical Imaging Interferon Therapy for Malignant Solid Tumors
Current Drug Therapy CXCR4 and CXCL12 Expression in Rectal Tumors of Stage IV Patients Before and After Local Radiotherapy and Systemic Neoadjuvant Treatment
Current Pharmaceutical Design Receptor Tyrosine Kinases as Therapeutic Targets in Malignant Glioma
Reviews on Recent Clinical Trials Cationic Polymers and their Self-Assembly for Antibacterial Applications
Current Topics in Medicinal Chemistry Gold and Silver Nanoparticles for Applications in Theranostics
Current Topics in Medicinal Chemistry Role of the Cannabinoid System in Pain Control and Therapeutic Implications for the Management of Acute and Chronic Pain Episodes
Current Neuropharmacology Structural and Mechanistic Bases of the Anticancer Activity of Natural Aporphinoid Alkaloids
Current Topics in Medicinal Chemistry Insight γ-Secretase: Structure, Function, and Role in Alzheimer’s Disease
Current Drug Targets Catatonia, Malignant Catatonia, and Neuroleptic Malignant Syndrome
Current Psychiatry Reviews The Circulating Endothelial Cell in Cancer: Towards Marker and Target Identification
Current Pharmaceutical Design Synthesis and Preliminary Evaluation of 5-[18F]fluoroleucine
Current Radiopharmaceuticals Soft Matter Assemblies as Nanomedicine Platforms for Cancer Chemotherapy: A Journey from Market Products Towards Novel Approaches
Current Topics in Medicinal Chemistry